{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:19:04Z","timestamp":1784823544143,"version":"3.55.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Biologics and small-molecule drugs have become increasingly accepted worldwide in the treatment of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). However, a quantitative multiple comparison of their efficacy and safety is lacking. This study aims to provide an integrated assessment of the relative benefits and safety profiles of these drugs in axSpA treatment.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We included randomized clinical trials that compared biologics and small-molecule drugs in the treatment of axSpA patients. The primary outcomes assessed were efficacy, including the Assessment of SpondyloArthritis International Society (ASAS) improvement of 20% (ASAS20) and 40% (ASAS40). Safety outcomes included treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). We used the surface under the cumulative ranking (SUCRA) curve value and ranking plot to evaluate and rank clinical outcomes and safety profiles of different treatments. The two-dimensional graphs were illustrated to visually assess both the efficacy (horizontal axis) and safety (vertical axis) of each intervention.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Our analysis included 57 randomized clinical trials involving a total of 11,787 axSpA patients. We found that seven drugs (TNFRFc, TNFmAb, IL17Ai, IL17A\/Fi, IL17RAi, JAK1\/3i, and JAK1i) were significantly more effective in achieving ASAS20 response compared to the placebo (PLA). Except for IL17RAi, these drugs were also associated with higher ASAS40 responses. TNFmAb demonstrated the highest clinical response efficacy among all the drugs. Subgroup analyses for AS and nr-axSpA patients yielded similar results. IL17A\/Fi emerged as a promising choice, effectively balancing efficacy and safety, as indicated by its position in the upper right corner of the two-dimensional graphs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our findings highlight TNFmAb as the most effective biologic across all evaluated efficacy outcomes in this network meta-analysis. Meanwhile, IL17A\/Fi stands out for its lower risk and superior performance in achieving a balance between efficacy and safety in the treatment of axSpA patients.<\/jats:p>","DOI":"10.3389\/fphar.2023.1226528","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T05:48:01Z","timestamp":1698212881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Erye","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatol. Oxf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/rmdopen-2015-000053","article-title":"Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?","volume":"1","author":"Baraliakos","year":"2015","journal-title":"RMD Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40744-016-0038-y","article-title":"Network meta-analysis and cost per responder of tumor necrosis factor-\u03b1 and interleukin inhibitors in the treatment of active ankylosing spondylitis","volume":"3","author":"Betts","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-022-02877-9","article-title":"A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis","volume":"24","author":"Burgos-Vargas","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"Cantini","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8316106","DOI":"10.1155\/2022\/8316106","article-title":"Optimal biologic drugs for the treatment of ankylosing spondylitis: results from a network meta-analysis and network metaregression","volume":"2022","author":"Cao","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","article-title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis","volume":"32","author":"Caso","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00296-016-3452-0","article-title":"Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern\/Central Europe, Latin America, and Asia","volume":"36","author":"Damjanov","year":"2016","journal-title":"Rheumatol. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","article-title":"Treatment of axial spondyloarthritis: an update","volume":"18","author":"Danve","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s10067-020-04970-3","article-title":"A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis","volume":"39","author":"Deodhar","year":"","journal-title":"Clin. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J. Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40744-020-00208-5","article-title":"Use and switching of biologic therapy in patients with non-radiographic axial spondyloarthritis: a patient and provider survey in the United States","volume":"7","author":"Deodhar","year":"","journal-title":"Rheumatol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13075-014-0481-5","article-title":"Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study","volume":"16","author":"Dougados","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B29","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","article-title":"A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis","volume":"30","author":"Giardina","year":"2010","journal-title":"Rheumatol. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5","volume":"133","author":"Huang","year":"2020","journal-title":"Chin. Med. J. Engl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s10067-021-05642-6","article-title":"Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey","volume":"40","author":"Hunter","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J. Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/1756-185X.13124","article-title":"A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis","volume":"21","author":"Khanna Sharma","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/acr.24184","article-title":"Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Lawson","year":"2021","journal-title":"Arthritis Care Res. Hob."},{"key":"B46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1159\/000525627","article-title":"Comparative efficacy and safety of janus kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis","volume":"107","author":"Lee","year":"2022","journal-title":"Pharmacology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejim.2022.04.007","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2022","journal-title":"Eur. J. Intern Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1741-7015-9-79","article-title":"Network meta-analysis-highly attractive but more methodological research is needed","volume":"9","author":"Li","year":"2011","journal-title":"BMC Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1136\/ard-2023-223937","article-title":"Response to: correspondence on \"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update\" by Braun et al","volume":"82","author":"Ramiro","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann. Rheumatic Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/14712598.2022.2152321","article-title":"What's new and what's next for biological and targeted synthetic treatments in psoriatic arthritis?","volume":"22","author":"Sunzini","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/rheumatology\/ket469","article-title":"The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis\u2014a randomized, placebo-controlled pilot trial","volume":"53","author":"Tam","year":"2014","journal-title":"Rheumatol. Oxf."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3899\/jrheum.201088","article-title":"A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis","volume":"48","author":"Taylor","year":"2021","journal-title":"J. Rheumatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Van Der Heijde","year":"","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"Van Der Heijde","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"Van Der Heijde","year":"","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"Van Der Heijde","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"Van Der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Van Der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B72","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"Van Der Heijde","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Van Der Heijde","year":"","journal-title":"Arthritis Rheum."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"Van Der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Van Der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"B76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"Van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B77","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"","journal-title":"Ann. Rheumatic Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/1756-185X.12973","article-title":"Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis","volume":"21","author":"Wei","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1226528\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T05:48:05Z","timestamp":1698212885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1226528\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":81,"alternative-id":["10.3389\/fphar.2023.1226528"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1226528","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"article-number":"1226528"}}